Bexagliflozin

贝沙格列净

Report date: 2026/02/06 20:01:23
NME

Base Information

Drug NameBexagliflozin
Drug Alias Name贝格列净bexagliflozinumbexagliflozinaBexagliflozin L-prolinebexagliflozine +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitors
TargetsSodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2Essential Hypertension
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date2023/01/20
Country/TerritoryCzechiaCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTheracos Inc
China Registration ClassN/A

Develop Information

Active CompaniesTheracosBio LLC
Inactive CompaniesTheracos IncPiramal Healthcare Uk LtdNewsoara Biopharma Co Ltd +[5] 
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsEssential Hypertension

Other Information

ATC CodeN/A
Related LinksKEGG